Stay updated with breaking news from Gene Therapy Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This CBM partnership with GTP is focused on moving therapeutics safely and rapidly from concept to clinic by connecting certain of Penn’s established gene therapy platforms with CBM’s manufacturing and analytical capacity.
Passage Bio is doubling down on its lead clinical program, a gene therapy designed to treat GM1 gangliosidosis, after interim clinical data from a Phase I/II trial showed developmental improvement in two young boys with the late infantile form of the inherited lysosomal storage disorder, after receiving a low dose of PBGM01.
Both children with late infantile GM1 gangliosidosis in Cohort 1 of the Imagine-1 clinical trial showed developmental improvement in assessments by study...
/PRNewswire/ -- The Center for Breakthrough Medicines (CBM) and the University of Pennsylvania's Gene Therapy Program (GTP) have signed a landmark...
/PRNewswire/ -- The Center for Breakthrough Medicines (CBM) and the University of Pennsylvania's Gene Therapy Program (GTP) have signed a landmark...